If so, then Treg present in the circulation of SCCHN patients might be a mix of less mature (CCR7+CD62L+) lymphocytes being recruited from the naïve lymphocyte pool and of activated or terminally differentiated Treg, which have lost either CCR7 or CCR7 and CD62L markers. The gene discussed is SELL; the disease is head and neck squamous cell carcinoma.